Glutathione Synthetase Deficiency Clinical Presentation
- Author: Darius J Adams, MD; Chief Editor: Luis O Rohena, MD more...
The phenotypic manifestations that have been described in association with glutathione synthetase (GS) deficiency include hemolytic anemia, which occurs in mild glutathione synthetase deficiency, and 5-oxoprolinuria (pyroglutamicaciduria) and variable degrees of secondary neurological involvement (occurring in systemic glutathione synthetase deficiency). As stated in Mortality/Morbidity, authors have suggested glutathione synthetase deficiency be described as mild, moderate, or severe. These categories represent a continuum of disease severity that depends on the degree of enzyme function; therefore, patients can have manifestations anywhere along the continuum of mild to severe glutathione synthetase deficiency.
- The severe phenotypic manifestation, 5-oxoprolinuria (pyroglutamicaciduria), resulting from systemic glutathione synthetase deficiency, is an autosomal recessive disorder. It is characterized by very large peaks of 5-oxoproline on urine organic acid analysis findings, metabolic acidosis, hemolytic anemia, and eventual CNS damage. Because of deficient enzyme activity, a decreased quantity of glutathione results, which likely causes promoter activation of the GSS gene. The large amounts of gamma-glutamylcysteine synthetase that are produced increase the pool of gamma-glutamylcysteine, which is then converted to 5-oxproline because of the inability of the defective GSS gene to produce glutathione.
- In moderate glutathione synthetase deficiency, neonatal acidosis and hemolytic anemia are present, but neurological involvement is not. The prognosis for the moderate form is intermediate.
- In mild glutathione synthetase deficiency, hemolytic anemia is the primary finding with apparently no effects outside of erythrocytes. Individuals with this form do well clinically.
Patients with glutathione synthetase deficiency appear healthy and do not have unusual dysmorphic features.
- In severe glutathione synthetase deficiency, neurological findings are the most prevalent and may include the following:
- Spasticity (spastic tetraparesis)
- Ataxia and other cerebellar findings
- Intention tremors
- Mental retardation
- Seizure disorders
- Eye abnormalities, which tend to be peripheral retinal pigmentation abnormalities
- Individuals with moderate glutathione synthetase deficiency may have apparent respiratory distress as their bodies try to correct metabolic acidosis; however, other signs are not usually present.
- In mild glutathione synthetase deficiency, physical findings are not present.
See the list below:
- Southern blot hybridizations that have been performed with a glutathione synthetase complementary DNA (cDNA) have revealed that only one GSS gene is present in the human genome. It is located at band 20q11.2.
- Pathogenic mutations in the GSS gene cause glutathione synthetase deficiency, which is inherited in an autosomal recessive pattern. Carriers of one abnormal allele do not have symptoms of the condition.
- These findings suggest that the different phenotypic types observed in glutathione synthetase deficiency are part of a spectrum of disease that depends on the degree of glutathione synthetase function.
Simon E, Vogel M, Fingerhut R, et al. Diagnosis of glutathione synthetase deficiency in newborn screening. J Inherit Metab Dis. 2009 Sep 2. [Medline].
Dahl N, Pigg M, Ristoff E, et al. Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Hum Mol Genet. 1997 Jul. 6(7):1147-52. [Medline].
Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010 May. 6(5):274-85. [Medline].
Manning NJ, Davies NP, Olpin SE, et al. Prenatal diagnosis of glutathione synthase deficiency. Prenat Diagn. 1994 Jun. 14(6):475-8. [Medline].
Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007 Aug. 7(4):355-9. [Medline].
Boxer LA, Oliver JM, Spielberg SP, et al. Protection of granulocytes by vitamin E in glutathione synthetase deficiency. N Engl J Med. 1979 Oct 25. 301(17):901-5. [Medline].
Bruggemann LW, Groenendaal F, Ristoff E, et al. Glutathione synthetase deficiency associated with antenatal cerebral bleeding. J Inherit Metab Dis. 2004. 27(2):275-6. [Medline].
Divry P, Roulaud-Parrot F, Dorche C, et al. 5-Oxoprolinuria (glutathione synthetase deficiency): a case with neonatal presentation and rapid fatal outcome. J Inherit Metab Dis. 1991. 14(3):341-4. [Medline].
Erasmus E, Mienie LJ, de Vries WN, et al. Prenatal analysis in two suspected cases of glutathione synthetase deficiency. J Inherit Metab Dis. 1993. 16(5):837-43. [Medline].
Fily A, Vaillant C, Truffert P. [Gluthathion synthetase deficit in a newborn infant.]. Arch Pediatr. 2004 Nov. 11(11):1339-41. [Medline].
Jellum E, Kluge T, Borresen HC, et al. Pyroglutamic aciduria--a new inborn error of metabolism. Scand J Clin Lab Invest. 1970 Dec. 26(4):327-35. [Medline].
Larsson A, Zetterstrom R, Hagenfeldt L, et al. Pyroglutamic aciduria (5-oxoprolinuria), an inborn error in glutathione metabolism. Pediatr Res. 1974 Oct. 8(10):852-6. [Medline].
Marstein S, Jellum E, Halpern B. Biochemical studies of erythrocytes in a patient with pyroglutamic acidemia (5-oxoprolinemia). New Engl J Med. 1976. 295:
Martensson J, Gustafsson J, Larsson A. A therapeutic trial with N-acetylcysteine in subjects with hereditary glutathione synthetase deficiency (5-oxoprolinuria). J Inherit Metab Dis. 1989. 12(2):120-30. [Medline].
Meister A, Anderson ME. Glutathione. Annu Rev Biochem. 1983. 52:711-60. [Medline].
Mohler DN, Majerus PW, Minnich V, et al. Glutathione synthetase deficiency as a cause of hereditary hemolytic disease. N Engl J Med. 1970 Dec 3. 283(23):1253-7. [Medline].
Njalsson R, Carlsson K, Winkler A, et al. Diagnostics in patients with glutathione synthetase deficiency but without mutations in the exons of the GSS gene. Hum Mutat. 2003 Dec. 22(6):497. [Medline].
Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr. 2001 Jul. 139(1):79-84. [Medline].
Robertson PL, Buchanan DN, Muenzer J. 5-Oxoprolinuria in an adolescent with chronic metabolic acidosis, mental retardation, and psychosis. J Pediatr. 1991 Jan. 118(1):92-5. [Medline].
Shi ZZ, Habib GM, Rhead WJ, et al. Mutations in the glutathione synthetase gene cause 5-oxoprolinuria. Nat Genet. 1996 Nov. 14(3):361-5. [Medline].
Spielberg SP, Boxer LA, Oliver JM, et al. Oxidative damage to neutrophils in glutathione synthetase deficiency. Br J Haematol. 1979 Jun. 42(2):215-23. [Medline].
Uhlig S, Wendel A. The physiological consequences of glutathione variations. Life Sci. 1992. 51(14):1083-94. [Medline].
Webb GC, Vaska VL, Gali RR, et al. The gene encoding human glutathione synthetase (GSS) maps to the long arm of chromosome 20 at band 11.2. Genomics. 1995 Dec 10. 30(3):617-9. [Medline].
Yapicioaylu H, Satar M, Tutak E. A newborn infant with generalized glutathione synthetase deficiency. Turk J Pediatr. 2004 Jan-Mar. 46(1):72-5. [Medline].